Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.
Checked against the public recordLast updated Jan 22, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Epic Sciences
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Suspected lung cancer * Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed * Age \>18 Exclusion Criteria: * Patients with history of a separate (not a primary lung cancer) malignancy within past two years. * Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc) * Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years. * Inability to provide informed consent. * Hgb less than 8.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Moores Cancer CenterLa Jolla, California
- Yale UniversityNew Haven, Connecticut
- Billings Clinic Cancer CenterBillings, Montana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 22, 2016. Always confirm current availability with the study team.